Universität zu Köln

Stegmayr, Carina, Stoffels, Gabriele, Filss, Christian, Heinzel, Alexander, Lohmann, Philipp ORCID: 0000-0002-5360-046X, Willuweit, Antje, Ermert, Johannes ORCID: 0000-0002-2561-7766, Coenen, Heinz H., Mottaghy, Felix M., Galldiks, Norbert and Langen, Karl-Josef (2021). Current trends in the use of O-(2-[F-18]fluoroethyl)-L-tyrosine ([F-18]FET) in neurooncology. Nucl. Med. Biol., 92. S. 78 - 85. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1872-9614

Full text not available from this repository.

Abstract

The diagnostic potential of PET using the amino acid analogue O-(2-[F-18]fluoroethyl)-L-tyrosine ([F-18]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [F-18]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [F-18]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [F-18]FET has widely replaced short lived amino acid tracers such as L-[C-11]methyl-methionine ([C-11]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [F-18]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [F-18]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed. (C) 2020 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Stegmayr, Carina UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoffels, Gabriele UNSPECIFIED UNSPECIFIED UNSPECIFIED Filss, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Heinzel, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Lohmann, Philipp UNSPECIFIED orcid.org/0000-0002-5360-046X UNSPECIFIED Willuweit, Antje UNSPECIFIED UNSPECIFIED UNSPECIFIED Ermert, Johannes UNSPECIFIED orcid.org/0000-0002-2561-7766 UNSPECIFIED Coenen, Heinz H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mottaghy, Felix M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Galldiks, Norbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Langen, Karl-Josef UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-596690
DOI:	10.1016/j.nucmedbio.2020.02.006
Journal or Publication Title:	Nucl. Med. Biol.
Volume:	92
Page Range:	S. 78 - 85
Date:	2021
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1872-9614
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language POSITRON-EMISSION-TOMOGRAPHY; DYNAMIC F-18-FET PET; AMINO-ACID PET; RECURRENT BRAIN METASTASIS; LOW-GRADE GLIOMA; O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET; RESPONSE ASSESSMENT; PROGNOSTIC VALUE; UPTAKE KINETICS; FET PET Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59669